Telix Pharmaceuticals Limited American Depositary Shares TLX
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $21.00 (+77.5% upside)
Key Stats
- Today's Range
- $11.63 – $12.22
- 50-Day Range
- $9.79 – $13.11
- 52-Week Range
- $6.28 – $13.11
- Volume
- 642K shs
- Average Volume
- 238K shs
- Market Cap
- $4.02 billion
- P/E Ratio
- —
- Dividend Yield
- 1.18%
Dividend
- Dividend Yield
- 1.18%
- Annual Dividend
- $0.14
- Payout Ratio
- —
- Ex-Dividend Date
- 2006-04-18
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Related Stocks
Compare head-to-head: TLX vs NVDA·TLX vs AAPL·TLX vs GOOGL·TLX vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.